Research Achievements

Presentations and Posters

2016


Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH


Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Oogami Masahiro, Honma Masato, Satoru Shimizu, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoshi Morita, Masakazu Toi


2016.12 SABCS Poster San Antonio, Texas

Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16)


Kosuke Kawaguchi, Eiji Suzuki, Tatsuki R Kataoka, Masahiro Hirata, Shinji Ohno, Hiroko Bando, Hiroshi Ishiguro, Kenichi Inoue, Naohito Yamamoto, Katsumasa Kuroi, Satoshi Morita, Norikazu Masuda, Masakazu Toi, Japan Breast Cancer Research Group (JBCRG)


2016 ASCO Poster

PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy (JBCRG-M05).


Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama, Naoki Niikura, Fumitaka Hara, Tomomi Fujisawa, Tetsuhiro Yoshinami, Shigehira Saji, Toshimi Takano, Norikazu Masuda, Satoshi Morita, Masakazu Toi, Shinji Ohno.


2016 ASCO Poster

Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17).


Naoto Kondo, Yoshinori Ito, Ippei Fukada, Shoichiro Ohtani, Masaya Hattori, Eriko Tokunaga, Nobuki Matsunami, Kohjiro Mashino, Taijiro Kosaka, Masahiko Tanabe, Daisuke Yotsumoto, Kosho Yamanouchi, Masataka Sawaki, Masahiro Kashiwaba, Hidetaka Kawabata, Katsumasa Kuroi, Satoshi Morita, Shinji Ohno, Masakazu Toi, Norikazu Masuda


2016 ASCO Poster

Search for appropriate treatment strategy using fulvestrant for postmenopausal ER-positive advanced or recurrent breast cancer patients in Japan (JBCRG-C06; Safari)


Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji,Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Shinji Ohno, Masakazu Toi


2016 EBCC Poster

Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE)


Naoto Kondo, Yutaka Yamamoto, Hiroyasu Yamashiro, Masahiro Kashiwaba, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno


2016 EBCC Poster

Presentations and Posters
by Voluntary Organization JBCRG